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Challenges in tracking global malaria spending
In The Lancet Infectious Diseases, Joseph Dieleman and 
colleagues describe how global malaria spending has 
changed between 2000 and 2016, using data from 
106 malaria-endemic countries. They analyse the 
proportions of government spending, out-of-pocket 
spending, and prepaid private contributions to total 
malaria spending, including the costs for treatment 
seeking, care, and drugs. Although total annual malaria 
spending has increased in this period to US$4·3 billion, 
they conclude that we are still off meeting target annual 
funding by 2020 by $2·3 billion.
If we take these results at face value, we can see 
development assistance for malaria increased by 
30·2% from 2000 to 2010. Since then, it has decreased 
annually by 1·9%, but by 2016, development assistance 
was nonetheless contributing to 56·5% of total malaria 
spending.1 Although out-of-pocket spending appears 
to have decreased from 26% (2000) to 13% (2016) of 
total malaria spending, it has actually seen an absolute 
increase of $249 million.1 Whereas absolute government 
expenditure has increased between 2000 and 2016, 
its percentage contributions have decreased from 55% 
(2000) to 28% (2016).1
However, these findings should be read with attention 
to the limitations of the underlying data and analysis. 
We highlight two in particular. First, in two of the 
study’s main sources, data availability for aggregate 
government spending did not include spending on 
malaria inpatient and outpatient care. These figures 
had to be calculated separately, by means of estimates 
on volume of care and prices for treatments. Although 
relying on estimates is widely used in global health, 
there is concern that we have become too reliant on 
them and should instead be investing in strengthening 
the capacity to produce quality data where it is absent.2,8 
We welcome the creation of credible estimates of total 
malaria spending, as well the authors’ initial steps 
towards identifying areas to improve data quality, but 
providing specific recommendations on what these 
improvements should consist of and how to achieve 
them should be an important point in all discussion 
sections for papers relying on such estimates.
Second, volumes of care were calculated on the basis 
of public treatment seeking and specifically treatment 
seeking for fever, and this method was also used for 
out-of-pocket spending calculations. However, use 
of fever as part of the methodology for estimating 
malaria cases has been widely criticised for contributing 
to the overdiagnosis and mistreatment of malaria;2 in 
particular, in malaria-endemic countries, most individuals 
presenting with fever are prescribed antimalarials.3–6 
These overestimations are likely to inflate the amount of 
out-of-pocket spending because they capture visits for 
fever, rather than visits for malaria alone.
Estimations of total malaria spending are valuable, as 
they fill a major gap in our knowledge of how malaria 
prevention and treatment is financed. Although it is 
useful to know that there is a difference in spending 
patterns related to a country’s malaria status, these 
estimations do not always translate into directly 
relevant information at the country and district levels.7
For example, one policy implication that Dieleman 
and colleagues stress is the need for an increase in 
government contributions to total malaria spending. 
Although we can all agree that more money would be 
beneficial, there are no clear suggestions on how this can 
be achieved, particularly in low-income countries. Rather 
they highlight some of the constraints such as poor tax 
collection, low population income, and corruption.9
The other important finding from this study is the 
absolute increase in out-of-pocket contributions to total 
malaria spending. Dieleman and colleagues highlight 
the increased affordability of malaria drugs and applaud 
the global effort to reduce costs. However, the burden of 
out-of-pocket payments is still high for the 500 million 
people living below the poverty line in malaria-endemic 
countries.1 One action that a health minister could take 
to address out-of-pocket spending would be to expand 
prepayment mechanisms to cover costs, such as health 
insurance or fee exemption schemes. This strategy 
must be approached with care, as certain approaches 
to extending prepayment mechanisms can undermine 
national progress toward universal health coverage. 
In the case of private prepayment systems for health, 
financial protection is shaped by demand, which 
depends on one’s willingness to purchase the item and 
ability to pay for it.10 Individuals might understand the 
need for insurance; however, a large proportion of the 
population affected by malaria will not be able to afford 
the premium (ie, membership fee), exacerbating health 
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inequity within the country, a defining principle of 
universal health coverage.
To conclude, although we welcome the creation of 
estimates for spending, more work needs to be done 
translating the findings of these types of financing 
studies into actionable and concrete strategies for 
governments and donors. Ultimately, some reflection 
is needed on how tracking financing data can help shift 
funding patterns to suit specific country’s needs, and 
thus produce tangible results towards malaria control 
and eradication.
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